OncoSec Medical (OTC:ONCS) reported Tuesday its president and chief executive Punit Dhillon has written an article for Today’s
biomedical company, founded in 2011, develops advance-stage
ElectroOncology anti-cancer therapies to treat people with solid
The article entitled “A Novel Delivery System”
chronicles the parts and processes governing use of the OncoSec Medical
System (OMS) technology platform.
Dhillon’s published article
also focuses on addressing the medical industry’s challenge to find safe
and effective methods for delivering potentially useful agents to treat
solid tumour cancers.
Currently, OncoSec is developing two
platforms using its proprietary technology which include the OMS
ElectroImmunotherapy program, now undergoing three ongoing Phase II
programs for rare and deadly skin cancers as well as the company's late
stage OMS ElectroChemotherapy program for the treatment of head and neck
The article can be read by clicking this link: http://www.onlinetmd.com/elecroporation-technology-cure-cancer.aspx
uses its electroporation delivery system which applies cell membrane
stimulation to deliver immunotherapy or chemotherapy to treat a range of
cancerous tumour types.
The OMS electroporation system has
proven to enhance cellular uptake, effectively treating cancerous cells
while sparing surrounding healthy tissue cutting through the toxic side
effects of current available treatment options like chemotherapy and
In 2011, the company managed to outline a clinical development plan for its local and potentially systemic ElectroImmunotherapy
program, which uses the OMS system to deliver a DNA-based immunotherapy, known as DNA IL-12.
IL-12 IS designed to induce a local immune response against the treated
cancerous tumour, while exploiting this response to initiate a global
systemic response against untreated tumours in other areas of the body.
For the metastatic melanoma trial, a total of up to 25 patients with stage three or four cutaneous and in-transit metastatic
melanoma will be enrolled in the phase two, single-arm, open-label and multi-centre study.